Hussain Borghaei, DO, MS | Authors


Pembrolizumab Improves 5-Year Survival in Advanced NSCLC in KEYNOTE-001

July 10, 2019

Hussain Borghaei, DO, MS, discusses the significance of the overall survival data update from the KEYNOTE-001 trial. This trial investigated the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced non–small cell lung cancer.